Related Experiment Video
Updated: Jan 5, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.1K
Novel berberine-based derivatives with potent hypoglycemic activity.
Jian-Ta Wang1, Jin-Gang Peng2, Ji-Quan Zhang3
1State Key Laboratory of Functions and Applications of Medicinal Plants, School of Pharmacy, Guizhou Medical University, Guiyang 550004, China; School of Basic Medical Sciences, Guizhou Medical University, Guiyang 550004, China; Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guiyang 550004, China.
Bioorganic & Medicinal Chemistry Letters
|October 21, 2019
Summary
New berberine derivatives show significant potential for managing blood glucose levels. The most effective compound demonstrated superior hypoglycemic activity compared to existing treatments by activating the AMPK pathway.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cell Biology
Background:
- Berberine is a natural compound with known hypoglycemic effects.
- Developing novel derivatives can enhance therapeutic efficacy.
- HepG2 cell lines are a standard model for studying glucose metabolism.
Purpose of the Study:
- To design and synthesize novel berberine derivatives.
- To evaluate the in vitro glucose consumption activity of these compounds.
- To elucidate the mechanism of action for potent derivatives.
Main Methods:
- Synthesis of four series of berberine derivatives.
- In vitro screening of glucose consumption in HepG2 cells.
- Western blot analysis to investigate pathway activation.
Main Results:
- Most synthesized compounds displayed significant hypoglycemic activity.
- Compound 20b showed superior potency compared to berberine, metformin, and rosiglitazone.
- Activation of the AMPK pathway was identified as the mechanism for glucose reduction.
Conclusions:
- Novel berberine derivatives possess potent glucose-lowering capabilities.
- Compound 20b represents a promising candidate for diabetes treatment.
- The AMPK pathway is crucial for the observed hypoglycemic effects.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
493
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
493
01:06Oral Hypoglycemic Agents: Glinides
549
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
549
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
550
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
550
01:17Oral Hypoglycemic Agents: Sulfonylureas
699
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
699
01:24Glucagon-like Receptor Agonists
798
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
798
01:23Dipeptidyl Peptidase 4 Inhibitors
537
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
537